Related Articles
Role of combining neutrophil‑to‑lymphocyte ratio and pretreatment body mass index in predicting progression‑free survival in patients with non‑small cell lung cancer treated with nivolumab
Platelet‑to‑lymphocyte and neutrophil‑to‑lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non‑small cell lung cancer
Value of neutrophil‑to‑lymphocyte ratio for predicting lung cancer prognosis: A meta‑analysis of 7,219 patients
Absolute lymphocyte count and C‑reactive protein‑albumin ratio can predict prognosis and adverse events in patients with recurrent esophageal cancer treated with nivolumab therapy
Prognostic value of the pretreatment neutrophil‑to‑lymphocyte ratio in patients with advanced gastrointestinal stromal tumors treated with sunitinib after imatinib failure